Quantitative and Comparative Analysis of Urinary Steroid Levels upon Treatment of an Anti-Diabetic Drug, CKD-501 using Gas Chromatography-Mass Spectrometry |
Sadanala, Krishna Chaitanya
(Integrated Omics Center, Korea Institute of Science and Technology)
Jung, Byung-Hwa (Integrated Omics Center, Korea Institute of Science and Technology) Jang, In-Jin (Department of Pharmacology, Clinical Pharmacology & Clinical Trials Center, Seoul National University College of Medicine & Hospital) Chung, Bong-Chul (Integrated Omics Center, Korea Institute of Science and Technology) |
1 | Norgren, S., Arner, P., Luthman, H., 1994. Insulin receptor ribonucleic acid levels and alternative splicing in human liver, muscle, and adipose tissue: tissue specificity and relation to insulin action. J. Clin. Endocrinol. Metab. 78, 757-762. DOI |
2 | Orasanu, G., Ziouzenkova, O., Devchand, P.R., Nehra, V., Hamdy, O., Horton E.S., Plutzky, J., 2008. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptoralpha-dependent manner in vitro and in vivo in mice. J. Am. Coll. Cardiol. 52, 869-881. DOI |
3 | Tomilson, J.W., Joanne, F., Christopher, G., Hughes, B.A., Susan, V. H., Paul, M. S., 2008. Impaired glucose tolerance and insulin resistance are associated with increased adipose dehydrogenase type 1 expression and elevated hepatic activity. Diabetes. 57, 2652-2660. DOI |
4 | Wang, Q., Dryden, S., Frankish, H. M., Bing, C., Pickavance, L., Hopkins, D., Buckingham, R., Williams, G., 1997. Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. Br. J. Pharmacol. 122, 1405-1410. DOI |
5 | Harris, M.I., Flegal, K.M., Cowie, C.C., Eberhardt, M.S., Goldstein, D.E., Little, R.R., Wiedmeyer, H.M., Byrd-Holt, D.D., 1998. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care. 21, 518-524. DOI |
6 | Hevener, A.L., Olefsky, J.M., Reichart, D., Nguyen M.T.A., Bandyopadyhay, G., Leung, H.Y., Watt, M.J., Benner, C., Febbraio, M.A., Nguyen, A.K., Folian, B., Subramaniam, S., Gonzalez, F.J., Glass, C.K., Ricote, M., 2007. Macrophage is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 117, 1658-1669. DOI ScienceOn |
7 | Jay, M.A., Ren, J., 2007. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr. Diabetes. 3, 33-39. DOI |
8 | Lee, J. H., Woo, T.A., Hwang, I.C., Kim, C. Y., Kim, D. D., Shim, C. K., Chung, S.J., 2009. Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies. J. Pharmaceut. Biomed. Anal. 50, 872-877. DOI |
9 | Kassirer, J.P., 1971. Clinical evaluation of kidney function − glomerular function. N. Engl. J. Med. 285, 385-389. DOI |
10 | Kempna, P., Hofer, G., Mullis, P.E., Fluck, C.E., 2007. Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. Mol. Pharmacol. 71, 787-798. |
11 | Moon, J.Y., Jung, H.J., Moon, M.H., Chung, B.C., Choi, M.H., 2009. Heat-map visualization of gas chromatography-mass spectrometry based quantitative signatures on steroid metabolism. J. Am. Soc. Mass Spectrom. 20, 1626-1637. DOI |
12 | Betz, M.J., Shapiro, I., Fassnacht, M., Hahner, S., Reincke, M., Beuschlein, F., 2005. Peroxisome proliferator-activated agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J. Clin. Endocrinol. Metab. 90, 3886-3896. DOI |
13 | Blaschke, F., Takata, Y., Caglayan, E., Law, R.E., Hsueh, W.A., 2006. Nuclear receptors as potential target for the treatment and prevention of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 26, 28-40. DOI |
14 | Desvergne, B., Michalik, L., Wahli, W., 2004. Be Fit or Be Sick: Peroxisome proliferator-activated receptors are down the road. Mol. Endocrinol. 18, 1321-1332. DOI |
15 | Froment, P., Gizard, F., Defever, D., Staels, B., Dupont, J., Monget, P., 2006. PPARs and RXRs in male and female fertility and reproduction. J. Endocrinol. 189, 199-209. DOI |
16 | Dzhamilja, S., Nadezhda, P., Enn, S., Alexander, Z., Allen, K., 2006. Dehydroepiandrosterone inhibits complex I of the mitochondrial respiratory chain and is neurotoxic In vitro and In vivo at high concentrations. Toxicological Sciences. 93(2), 348-356. DOI |
17 | Ferre, P., 2004. The biology of peroxisome proliferator-activated receptors. Diabetes. 53, S43-S50. DOI ScienceOn |
18 | Freeman, D.A., Romero, A., 2003. Effects of troglitazone on intracellular cholesterol distribution and cholesterol-dependent cell functions in MA-10 Leydig tumor cells. Biochem. Pharmacol. 66, 307-313. DOI |
19 | Galina, A., Roberto, A.S.S., Zoltan, B., Radina, M.K., Alex, O., 2005. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am J. Physiol. Endocrinol. Metab. 288, E957-E964. DOI |
20 | Baxter, J.D., Rousseau, G.G., 1979. Glucocorticoid hormone action: an overview. Monogr. Endocrinol. 12, 1-24. |
21 | Berthiaume, M., Sell, H., Lalonde, J., Gelinas, Y., Tchernof, A., Richard, D., Deshaies, Y., 2004. Actions of PPARγ agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids. Am J. Physiol. Regul. Integr. Comp Physiol. 287, R1116-R1123. DOI |